A UCLA study shows that a new treatment combining a radioactive drug with radiation therapy could help delay hormone therapy ...

Researchers report longer progression-free survival when Lutetium-177 was combined with standard radiotherapy for limited ...

A study led by UCLA Health Jonsson Comprehensive Cancer Center investigators found that stereotactic body radiotherapy (SBRT) ...

A shorter radiation course improved quality of life among men with intermediate-risk, localized prostate cancer, according to ...

For patients with intermediate-risk, localized prostate cancer, radiation therapy delivered in five sessions reduced ...

Patients with recurring prostate cancer who were treated with a new PSMA-targeted radioligand therapy before stereotactic ...

Physicians and scientists from the UCLA Health Jonsson Comprehensive Cancer Center will share the latest research and ...

Median progression-free survival (PFS) increased from 7.4 months with stereotactic body radiotherapy (SBRT) to 17.6 months with the addition of 177 lutetium (Lu) PNT2002 targeting prostate-specific ...

MiraDx, a molecular diagnostics company focused on genetic testing to personalize cancer treatment, announced today that its PROSTOX ultra test is now available for ordering in the United States. The ...

A new clinical trial finds that people with a limited number of metastases from recurrent prostate cancer lived significantly ...